/
NMRA
$1.72+$0.08 (+4.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$303.9M
185M shares
52-week range
$0.72 – $3.65
34% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
5.20%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-14.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $668.0K | $0 | $5.0M |
| Gross profit | $0 | $0 | $0 | −$668.0K | $0 | −$5.0M |
| Gross margin | — | — | — | — | — | — |
| R&D | $87.1M | $212.8M | $104.7M | $142.7M | $200.9M | $176.1M |
| Operating income | −$95.5M | −$237.3M | −$135.9M | −$188.2M | −$263.5M | −$241.2M |
| EBITDA | −$95.4M | −$236.8M | −$130.3M | −$235.0M | −$243.0M | −$233.4M |
| Net income | −$99.3M | −$237.3M | −$130.9M | −$235.9M | −$243.8M | −$236.9M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.65 | -1.56 | -0.86 | -1.49 | -1.53 | -1.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $625000 | $-0.91 | $-1.23–$-0.64 | 7 |
| 2027 | $5M | $-0.77 | $-1.11–$-0.35 | 7 |
| 2028 | $54M | $-0.76 | $-1.10–$-0.18 | 7 |
| 2029 | $161M | $-0.45 | $-0.45–$-0.45 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.10
Price
$1.72
Implied downside
-36%
Peer comparison
Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
www.neumoratx.com- Employees
- 92
- IPO / List date
- Sep 15, 2023
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds NMRA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,388,998 | $2.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NMRA yet.
